{"transactions":[{"id":3072796,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Free Shares Call Options (obligation to sell to Issuer)","published_at":"2020-08-01T00:16:25.000Z","date":"2020-07-03","kind":"other","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 3, 2020, the Free Shares Call Option with respect to the third tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On July 3, 2020, the Free Shares Call Option with respect to the third tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised."}],"balance_after":1,"derivative":{"exercise_date":"2020-05-03","expiration_date":"2020-07-03","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001209191-20-044347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120044347/doc4.xml","form_type":"4"}},{"id":3072795,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Free Shares Call Options (obligation to sell to Issuer)","published_at":"2020-08-01T00:16:25.000Z","date":"2020-05-09","kind":"other","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning May 3, 2019 (the \"Free Shares Call Options\"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On May 9, 2020, the Free Shares Call Option with respect to the second tranche of Subject Free Shares (or 80,000 Subject Free Shares) expired unexercised."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning May 3, 2019 (the \"Free Shares Call Options\"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On May 9, 2020, the Free Shares Call Option with respect to the second tranche of Subject Free Shares (or 80,000 Subject Free Shares) expired unexercised."}],"balance_after":2,"derivative":{"exercise_date":"2020-03-09","expiration_date":"2020-05-09","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001209191-20-044347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120044347/doc4.xml","form_type":"4"}},{"id":3121039,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Free Shares Put Option (right to sell to Issuer)","published_at":"2020-06-06T01:29:27.000Z","date":"2020-06-04","kind":"exercise","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(or 80,000 Subject Free Shares) (the \"Second Tranche Shares\") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"(or 80,000 Subject Free Shares) (the \"Second Tranche Shares\") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."}],"balance_after":2,"derivative":{"exercise_price":2.0925,"exercise_date":"2020-05-10","expiration_date":"2020-07-10","underlying":"Common Stock","underlying_shares":14907},"source":{"system":"sec-edgar","filing":"0001209191-20-034882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120034882/doc4.xml","form_type":"4"}},{"id":3121038,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Common Stock","published_at":"2020-06-06T01:29:27.000Z","date":"2020-06-04","kind":"disposition_to_issuer","acquired":false,"shares":14907,"price":11.23,"value":167405.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(or 80,000 Subject Free Shares) (the \"Second Tranche Shares\") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."}],"balance_after":70116,"source":{"system":"sec-edgar","filing":"0001209191-20-034882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120034882/doc4.xml","form_type":"4"}},{"id":3121037,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Common Stock","published_at":"2020-06-06T01:29:27.000Z","date":"2020-06-04","kind":"exercise","acquired":true,"shares":14907,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(or 80,000 Subject Free Shares) (the \"Second Tranche Shares\") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(or 80,000 Subject Free Shares) (the \"Second Tranche Shares\") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."}],"balance_after":85023,"source":{"system":"sec-edgar","filing":"0001209191-20-034882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120034882/doc4.xml","form_type":"4"}},{"id":3247062,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Stock Option (Right-to-Buy)","published_at":"2020-02-27T00:31:10.000Z","date":"2020-02-25","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person\nmeasured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six\n(36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":110000,"derivative":{"exercise_price":6.8,"expiration_date":"2030-02-24","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-20-013229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120013229/doc4.xml","form_type":"4"}},{"id":3247061,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Common Stock","published_at":"2020-02-27T00:31:10.000Z","date":"2020-02-25","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 55,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on\neach anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting\nPerson's continued service with the Issuer through such dates."}],"balance_after":70116,"source":{"system":"sec-edgar","filing":"0001209191-20-013229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120013229/doc4.xml","form_type":"4"}},{"id":3247060,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Common Stock","published_at":"2020-02-27T00:31:10.000Z","date":"2020-02-25","kind":"tax_withholding","acquired":false,"shares":2384,"price":6.8,"value":16211.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of the restricted stock unit grant that vested on February 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2020 of $6.80/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,449 shares resulting from the February 25, 2020 vesting of Reporting Person's February 25, 2019 restricted stock unit grant and\n11,667 shares subject to such restricted stock unit grant that will vest in two remaining annual installments on February 25, 2021 and February\n25, 2022, resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting\nPerson's continued service with the Issuer through such dates."}],"balance_after":15116,"source":{"system":"sec-edgar","filing":"0001209191-20-013229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120013229/doc4.xml","form_type":"4"}},{"id":3277939,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strategy"}}],"security":"Free Shares Call Options (obligation to sell to Issuer)","published_at":"2020-02-12T23:33:00.000Z","date":"2019-07-03","kind":"other","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning May 3, 2019 (the \"Free Shares Call Options\"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329.  On July 3, 2019, the Free Shares Call Option with respect to the first tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning May 3, 2019 (the \"Free Shares Call Options\"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329.  On July 3, 2019, the Free Shares Call Option with respect to the first tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised."}],"balance_after":3,"derivative":{"exercise_date":"2019-05-03","expiration_date":"2019-07-03","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001209191-20-008969","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120008969/doc5.xml","form_type":"5"}},{"id":3439155,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strat. & Int. CFO"}}],"security":"Free Shares Put Option (right to sell to Issuer)","published_at":"2019-08-14T21:10:19.000Z","date":"2019-08-12","kind":"exercise","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(or 52,700 Subject Free Shares) (the \"First Tranche Shares\") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"(or 52,700 Subject Free Shares) (the \"First Tranche Shares\") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."}],"balance_after":3,"derivative":{"exercise_price":2.37,"exercise_date":"2019-07-04","expiration_date":"2021-02-03","underlying":"Common Stock","underlying_shares":11137},"source":{"system":"sec-edgar","filing":"0001209191-19-045963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119045963/doc4.xml","form_type":"4"}},{"id":3439154,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strat. & Int. CFO"}}],"security":"Common Stock","published_at":"2019-08-14T21:10:19.000Z","date":"2019-08-12","kind":"disposition_to_issuer","acquired":false,"shares":11137,"price":11.23,"value":125068.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(or 52,700 Subject Free Shares) (the \"First Tranche Shares\") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001209191-19-045963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119045963/doc4.xml","form_type":"4"}},{"id":3439153,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strat. & Int. CFO"}}],"security":"Common Stock","published_at":"2019-08-14T21:10:19.000Z","date":"2019-08-12","kind":"exercise","acquired":true,"shares":11137,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(or 52,700 Subject Free Shares) (the \"First Tranche Shares\") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329.  On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(or 52,700 Subject Free Shares) (the \"First Tranche Shares\") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash.  The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise."}],"balance_after":28637,"source":{"system":"sec-edgar","filing":"0001209191-19-045963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119045963/doc4.xml","form_type":"4"}},{"id":3439157,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strat. & Int. CFO"}}],"security":"Free Shares Put Options (right to sell to Issuer)","published_at":"2019-08-14T21:04:31.000Z","date":"2018-11-27","kind":"other","acquired":true,"shares":4,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In connection with the acquisition by the Issuer of Sangamo France, in addition to the grant to the Issuer of the Free Shares Call Options, the Reporting Person was granted the right to sell to the Issuer the Subject Free Shares for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\"), which Free Shares Put Options shall be exercisable to the extent that the corresponding Free Shares Call Options are not exercised by the Issuer.  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of his exercise of his Free Shares Put Options (as converted to euros) divided by 12.8329."},{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the acquisition by the Issuer of Sangamo France, in addition to the grant to the Issuer of the Free Shares Call Options, the Reporting Person was granted the right to sell to the Issuer the Subject Free Shares for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\"), which Free Shares Put Options shall be exercisable to the extent that the corresponding Free Shares Call Options are not exercised by the Issuer.  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of his exercise of his Free Shares Put Options (as converted to euros) divided by 12.8329."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"In connection with the acquisition by the Issuer of Sangamo France, in addition to the grant to the Issuer of the Free Shares Call Options, the Reporting Person was granted the right to sell to the Issuer the Subject Free Shares for cash in four separate tranches beginning July 4, 2019 (the \"Free Shares Put Options\"), which Free Shares Put Options shall be exercisable to the extent that the corresponding Free Shares Call Options are not exercised by the Issuer.  The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of his exercise of his Free Shares Put Options (as converted to euros) divided by 12.8329."}],"balance_after":4,"derivative":{"exercise_date":"2019-07-04","expiration_date":"2021-02-03","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001209191-19-045960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119045960/doc4.xml","form_type":"4"}},{"id":3439156,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corp. Strat. & Int. CFO"}}],"security":"Free Shares Call Options (obligation to sell to Issuer)","published_at":"2019-08-14T21:04:31.000Z","date":"2018-11-27","kind":"other","acquired":false,"shares":4,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person granted to the Issuer the right to purchase up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning May 3, 2019 (the \"Free Shares Call Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person granted to the Issuer the right to purchase up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning May 3, 2019 (the \"Free Shares Call Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) (\"Sangamo France\"), the Reporting Person granted to the Issuer the right to purchase up to 238,100 \"free shares\" of Sangamo France (the \"Subject Free Shares\") for cash in four separate tranches beginning May 3, 2019 (the \"Free Shares Call Options\").  The exercise price per Subject Free Share to be paid by the Issuer upon exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329."}],"balance_after":4,"derivative":{"exercise_date":"2019-05-03","expiration_date":"2020-12-02","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001209191-19-045960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119045960/doc4.xml","form_type":"4"}},{"id":3629878,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corporate Strategy"}}],"security":"Stock Option (Right-to-Buy)","published_at":"2019-02-28T01:20:00.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":105000,"derivative":{"exercise_price":9.03,"expiration_date":"2029-02-24","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-19-014302","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119014302/doc4.xml","form_type":"4"}},{"id":3629877,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corporate Strategy"}}],"security":"Common Stock","published_at":"2019-02-28T01:20:00.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents 17,500 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001209191-19-014302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119014302/doc4.xml","form_type":"4"}},{"id":3753187,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":147517,"kind":"person","name":"Boissel Stephane","position":1,"cik":"0001755198","reported_name":"Boissel Stephane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corporate Strategy"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-27T02:11:32.000Z","date":"2018-11-23","kind":"grant","acquired":true,"shares":283523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 68,523 option shares granted to the Reporting Person pursuant to the July 20, 2018 Share Purchase Agreement between the Issuer and certain shareholders of TxCell S.A. and 215,000 option shares granted pursuant to the  Reporting Person's October 2, 2018 employment agreement with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares vest and become exercisable after one (1) year measured from the November 23, 2018 grant date, and the remainder of the option shares will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":283523,"derivative":{"exercise_price":11.08,"expiration_date":"2028-11-22","underlying":"Common Stock","underlying_shares":283523},"source":{"system":"sec-edgar","filing":"0001209191-18-059976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919118059976/doc4.xml","form_type":"4"}}]}